Lower Dose Covid-19 Vaccine Protects Against Future Variants
Broad-spectrum mRNA SARS-CoV-2 Vaccine
Tags: Monash University, Australia, Healthcare & Lifesciences
A novel SARS-CoV-2 mRNA vaccine, encapsulated by a unique lipid nanoparticle, targets multiple COVID-19 variants with intramuscular or intravenous administration. This vaccine stimulates broad-spectrum anti-SARS-CoV-2 antibodies, addressing the unmet need for reducing transmission, especially in asymptomatic carriers and the elderly. It overcomes immune imprinting issues by inducing protection against current and emerging strains, with a lower dose and enhanced safety profile. The technology is adaptable for new variants, promising for global vaccination strategies. Its applications extend to preventing outbreaks in vulnerable populations and curbing the pandemic's spread.
IP Type or Form Factor: Patent Pending; Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Vaccines; Pharmaceutical Engineering
